Benefit-risk assessment of raloxifene in postmenopausal osteoporosis

Drug Safety

Volumn 28, Issue 8, 2005, Pages 721-730

  Cranney, Ann ^a,c   Adachi, Jonathan D ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLESTYRAMINE; DIAZEPAM; LEVOTHYROXINE; LIDOCAINE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; WARFARIN;

BONE DENSITY; CATARACT; CLINICAL TRIAL; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EOSINOPHILIA; EROSION; ESOPHAGUS DISEASE; FLU LIKE SYNDROME; FLUSHING; FRACTURE; GASTROINTESTINAL DISEASE; HEPATITIS; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; JAUNDICE; LEG CRAMP; LUNG EMBOLISM; MASTALGIA; OSTEOPENIA; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; RALOXIFENE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 23644458909     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528080-00006     Document Type: Review

References (74)

1. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fractures in the year following a fracture. JAMA 2001; 285: 320-3
2. Papaioannou A, Wiktorowicz M, Adachi JD, et al. Mortality, independence in living, and re-fracture, one year following hip fracture in Canadians. J Soc Obstet Gynecol Can 2000; 22: 591-7
3. Tosteson ANA, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209-16
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33
5. Evista [product monograph]. Ontario: Eli Lilly Canada Inc., 2000
6. Center for Drug Evaluation and Research. Food and Drug Administration Division of Metabolic and Endocrine Products. Medical review, supplemental NDA for raloxifene hydrochloride, 1999
7. US FDA. Adverse events/raloxifene. Medwatch [online]. Available from URL: http://www.fda.gov/medwatch [Accessed 2004 Nov 1]
8. Bryant HU. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulator. Rev Endocr Metab Disord 2001; 2: 129-38
9. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003; 9: 1980-9
10. Yang NN, Venugopalan M, Hardikar S, et al. Identification of an estrogen response element activated by metabolites of 17beta estradiol and raloxifene. Science 1996; 273: 1222-5
11. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-29
12. Meunier PJ, Vignot E, Gernero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 1999; 10: 330-6
13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-45
14. Bjarnason NH, Sarkar D, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk after 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922-30
15. Gluck O, Maricic M. Raloxifene: recent information on skeletal and non-skeletal effects. Curr Opin Rheumatol 2002; 14: 429-32
16. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003; 42: 361-72
17. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 2003; 41: 331-45
18. Miller JW, Skerjanec A, Knadler MP, et al. Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res 2001; 18: 1024-8
19. Siraj ES, Gupta MK, Reddy SSK. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003; 163: 1367-70
20. Johnell O, Scheele W, Lu Y, et al. Additive effects of raloxifene (RLX), alendronate (ALN) and RLX + ALN on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 985-92
21. Pavo I, Masanauskaite D, Rojinskaya L, et al. Effects of raloxifene versus placebo on bone mineral density in postmenopausal women in the absence of calcium supplementation [abstract]. J Bone Miner Res 1999; 14: S410
22. Lufkin EG, Whitaker MD, Nickelesen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747-54
23. Reid IR, Eastell R, Fogelman I, et al. A comparison of raloxifene with estrogen replacement therapy in normal postmenopausal women. Arch Intern Med 2004; 164: 871-9
24. Delmas PD, Bjarnson NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7
25. Johnston CC. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444-50
26. National Institute for Clinical Excellence. Appraisal consultation document: technologies for the prevention and treatment of osteoporosis and prevention of osteoporotic fractures in postmenopausal women [online]. Available from URL: www.-nice.org [Accessed 2004 Dec 1]
27. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003; 33: 293-300
28. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four year results from a randomized clinical trial. J Clin Endocrinol Metab 2003; 87: 3609-17
29. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postme-nopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140-3
30. Delmas PD, Genant HK, Crans GC, et al. Severity of prevalent fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-32
31. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 2002: 1-10
32. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003; 14: 814-22
33. Cranney A, Tugwell P, Krolicki N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 524-8
34. Palomba S, Orio F, Morelli M, et al. Roloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 2004; 87: 4476-81
35. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures: Fracture Intervention Trial Research Group. Ann Intern Med 1998; 128: 793-800
36. Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001; 44: 2611-9
37. Strickler R, Stovall DW, Merritt D, et al. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000; 96: 359-65
38. Utian WH, Janata JW, Barbier S, et al. Effect on quality of life: a prospective study using the Utian Quality of Life (UQOL) scale. Menopause 2004; 11: 275-80
39. Modugno F, Ness R, Ewing S, et al. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol 2003; 101: 353-61
40. Nickelsen T, Lufkin EG, Riggs BL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999; 24: 115-28
41. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in raloxpostmenopausal women treated with raloxifene. N Engl J Med 2001; 344: 1207-13
42. Barrett Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57
43. Barrett-Connor E, Ensrud KE, Harper K, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25: 919-30
44. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart study (RUTH). Am J Cardiol 2001; 88: 392-5
45. Jolly EE. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10: 337-44
46. Cohen FJ, Watts S, Shah A, et al. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000; 95: 104-10
47. Neven P, Lunde T, Benedetti-Panici P, et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate: Euralox 1 Study Group. BJOG 2003; 110: 157-67
48. Maia Jr H, Maltez A, Oliveira M, et al. Growth of an endometrial polyp in a postmenopausal patient using raloxifene. Gynecological Endoscopy 2000; 9: 117-21
49. Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558-65
50. Cummings SR, Eckert S, Krueger KA. The effects of raloxifene on risk of breast cancer in postmenopausal women treated with raloxifene: results from the MORE randomized trial. JAMA 1999; 281: 2189-97
51. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 2001; 65: 125-34
52. Cuzick J, Powles T, Veronesi U, et al. Overview of main outcomes in the breast cancer prevention trials. Lancet 2003; 361: 296-300
53. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61
54. Vogel VG, Constantino JP, Wickerham DL, et al. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002; 3: 153-9
55. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement study. Ann Intern Med 2000; 132: 689-96
56. Azevedo GD, Franco RF, Baggio MS, et al. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. Climacteric 2003; 6: 140-5
57. Layton D, Clarke A, Wilton L, et al. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporosis Int 2005; 11: 490-500
58. Vilches AR, Perez V, Sucheck DE. Raloxifene associated hepatitis. Lancet 1998; 352: 1524-5
59. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104: 837-44
60. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. Mammographic changes associated wtih raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002; 9: 110-6
61. Lee CC, Kasa-Vubu JZ, Supiano MA. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women. J Am Geriatr Soc 2003; 51: 683-8
62. Cranney A, Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8
63. Luckey M, Kagan R, Greenspan S, et al. Once-weekly alendronate 70mg and raloxifene 60mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004; 11: 405-15
64. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone mineral density: result of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004; 255: 503-11
65. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
66. Cranney A, Guyatt G, Willan A, et al. A meta-analysis of alendronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 508-16
67. Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in osteoporosis. Drugs 2001; 61: 999-1039
68. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95: 3112-7
69. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41
70. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoprosis: a randomized controlled trial. JAMA 1999; 282: 1344-52
71. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40
72. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal safety profile of alendronate: the fracture prevention trial. Arch Intern Med 2000; 160: 517-25
73. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77: 262-70
74. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Scientific Advisory Council of the Osteoporosis Society of Canada. CMAJ 2002; 167: S1-S34